HOME

NEWS

INFORMATION ON EFSPI

ADVERTISEMENTS

PUBLICATIONS

CALENDAR OF EVENTS

EFSPI ACTIVITIES

LINKS

LEAVE YOUR MESSAGE

SIGN UP TO OUR NEWSLETTER

ADVERTISEMENTS

JOB POSTINGS
SERVICES
PRODUCTS

publications

Top Level | Regulatory_comments

	Title	Submitted	File
	EFSPI comments on the EMA's Reflection paper on methodological issues associated with pharmacogenomic biomarkers Description: EFSPI comments on the EMA's Reflection paper on methodological issues associated with pharmacogenomic biomarkers in relation to clinical development and patient selection	October 2011	VIEW DOCUMENT
	EFSPI comments on EMA 'Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available' Description: EFSPI comments on EMA 'Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available'	March 2011	VIEW DOCUMENT
	EFSPI comments on draft FDA 'Guidance for Industry – Adaptive Design Clinical Trials for Drugs and Biologics' Description: EFSPI comments on draft FDA 'Guidance for Industry – Adaptive Design Clinical Trials for Drugs and Biologics'	July 2010	VIEW DOCUMENT
	EFSPI comments on draft FDA 'Guidance for Industry - Non-Inferiority Clinical Trials' Description: EFSPI comments on Draft FDA''Guidance for Industry - Non-Inferiority Clinical Trials'	May 2010	VIEW DOCUMENT
	EFSPI comments on EMEA CHMP guideline on missing data	December 2009	VIEW DOCUMENT
	EFSPI comments on EMEA CHMP guideline on the investigation of bioequivalence	January 2009	VIEW DOCUMENT

ADVERTISEMENTS | JOB POSTINGS | SERVICES | PRODUCTS

© 2007 EFSPI